Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Krystal discontinues melanoma study after FDA’s Replimune rebuff
The FDA’s rebuff of Replimune’s melanoma candidate has rippled across the industry, prompting Krystal Biotech to shutter a clinical trial.
Gabrielle Masson
Aug 21, 2025 10:50am
Sponsored
Investigational Rosnilimab Emerges as a Novel
Aug 18, 2025 8:00am
Kite sails into in vivo CAR-T space via $350M Interius buyout
Aug 21, 2025 9:59am
FDA aims for September approval decision for Stealth's drug
Aug 21, 2025 10:15am
After 'complete standstill,' biotech market reaches new normal
Aug 20, 2025 11:04am
Masimo sues US Customs over Apple Watch pulse ox green light
Aug 21, 2025 11:15am
More News
Fierce Pharma
Sarepta extends $700M debt to 2030 amid Elevidys uncertainty
Aug 21, 2025 10:52am
Dynavax's vaccine holds its own against Shingrix in early test
Aug 21, 2025 8:00am
Fierce Healthcare
After shooting, HHS staff call for RFK to stop sowing mistrust
Aug 20, 2025 1:38pm
IQVIA, Veeva go from adversaries to partners
Aug 20, 2025 1:32pm